Abstract
Revolution Medicines, Inc. will release quarterly results on November 04, 2026 Post-Mkt; this preview synthesizes consensus forecasts, the company’s prior-quarter baselines, and recent institutional views to frame expectations and key watch items.
Market Forecast
Consensus compiled from the latest finance tool inputs implies Revolution Medicines, Inc.’s current quarter revenue estimate is 25.48 million US dollars, representing 15.11% year-over-year growth, with forecast EPS at -2.40 and EBIT at -524.32 million US dollars; year-over-year forecasts imply EPS down 69.27% and EBIT contracting 85.59%. Forecast details on gross profit margin and net profit margin are not available in the tool’s dataset for the current quarter. The main business remains collaboration revenue, which is expected to be modest and milestone-driven; the company’s pipeline updates could frame near-term variability in recognized collaboration income. The business with the largest potential near-term contribution is collaboration revenue at 11.58 million US dollars last quarter, though reported year-over-year growth was not disclosed by the tool.
Last Quarter Review
Last quarter, Revolution Medicines, Inc. posted a GAAP net loss attributable to the parent of -644.00 million US dollars with a quarter-on-quarter change of -41.99%, revenue primarily from collaboration at 11.58 million US dollars, while gross margin, net profit margin, and adjusted EPS were not provided by the dataset. A key financial highlight was a larger-than-estimated operating loss, as EBIT actuals were -505.13 million US dollars versus an estimate of -421.92 million US dollars, and adjusted EPS (tool proxy) was -3.06 versus an estimate of -1.98, reflecting deeper R&D and precommercial investments. Main business activity centered on collaboration revenue of 11.58 million US dollars; the tool did not provide a year-over-year comparison for this line.
Current Quarter Outlook
Main business: Collaboration revenue trajectory
Collaboration income remains the principal recognized revenue stream for Revolution Medicines, Inc. in the absence of broad commercial product sales, and the finance tool points to a revenue estimate of 25.48 million US dollars for the current quarter. Timing of partner-driven milestones and service deliverables can create quarter-to-quarter lumpiness, which is reflected in the step-up from the prior quarter’s 11.58 million US dollars. Investors will monitor disclosures on any new milestone achievements, expanded scopes of existing alliances, or newly signed partnerships that could sustain double-digit revenue growth beyond this quarter. Visibility into contracted but unrecognized collaboration consideration would also help gauge durability of the 15.11% year-over-year growth implied by the forecast.
Most promising business: RAS-pathway pipeline catalysts and potential revenue inflection
While recognized revenue today is dominated by collaboration accounting, the greatest upside potential ties to late-stage RAS-pathway assets approaching pivotal milestones. The tool’s news flow window highlights repeated positive rating reiterations and price target increases tied to daraxonrasib and the broader KRAS/RAS portfolio, underscoring the market’s anticipation of regulatory and clinical readouts that could reframe the company’s medium-term revenue base. If pivotal data readouts or regulatory events progress on the timelines embedded in analysts’ models, management commentary could start to shape a path from milestone-weighted revenue to a future product revenue mix, even if near-term reported revenue still reflects collaborations. Any early signals on prelaunch activities, label scope assumptions, or commercialization readiness would be pivotal for modeling post-approval sales curves.
Stock price drivers this quarter: Operating burn, EPS trajectory, and pipeline de-risking
Two quantitative levers and one qualitative lever appear most relevant for the stock near the print. First, the EPS trajectory: the forecast for -2.40 this quarter versus last quarter’s -3.06 suggests an improvement in per-share loss, but still implies substantial investment; any variance will likely come from R&D phasing and non-cash items. Second, operating burn: forecast EBIT of -524.32 million US dollars indicates ongoing scaling of clinical and precommercial spending; granular guidance on R&D allocation by program and timing of spend tapering will shape runway assessments. Third, pipeline de-risking: updates on late-stage programs within the RAS portfolio could outweigh near-term P&L noise; clarity on trial enrollment status, event rates, and regulatory interactions would influence the risk-adjusted valuation more than collaboration revenue beats or misses of a few million.
Analyst Opinions
Recent institutional commentary skews decisively bullish. In the past six months, multiple research houses reiterated Buy ratings, including Guggenheim (price target 275 US dollars), LifeSci Capital (maintained 315 US dollars and reiterated several times around strengthening KRAS G12D leadership and daraxonrasib updates), J.P. Morgan (price target 246 US dollars), RBC Capital (price target 251 US dollars), and Bank of America (price target 225 US dollars), while one notable Hold came from Bernstein (price target 179 US dollars). The ratio of bullish to neutral/bearish views is overwhelmingly tilted toward bullish, with at least eight positive notes versus one Hold in the period captured by the news tool. Analysts point to regulatory momentum for the RAS portfolio, clinical strength around daraxonrasib and zoldonrasib data in pancreatic cancer subpopulations, and ongoing upsizing or advancement of pivotal studies as key supports for the equity story. The majority view emphasizes that near-term collaboration revenue is not the central thesis; rather, valuation hinges on de-risking of late-stage assets, the potential for a first commercial launch within the RAS franchise, and clarity on prelaunch demand indicators. Price targets well above current consensus-implied intrinsic value ranges suggest that successful near-term execution on clinical and regulatory milestones could catalyze further rerating, even if quarterly P&L remains loss-making under continued R&D investment.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments